SANOFI ADR

NASDAQ: SNY (Sanofi)

Last update: 07 Mar, 9:18PM

59.25

-0.17 (-0.29%)

Previous Close 59.42
Open 59.15
Volume 3,311,340
Avg. Volume (3M) 2,554,861
Market Cap 148,550,418,432
Price / Earnings (TTM) 25.00
Price / Earnings (Forward) 11.29
Price / Sales 2.66
Price / Book 1.48
52 Weeks Range
45.22 (-23%) — 59.72 (0%)
Earnings Date 24 Apr 2025
TTM Dividend Yield 6.88%
Profit Margin 12.56%
Operating Margin (TTM) 13.99%
Diluted EPS (TTM) 2.40
Quarterly Revenue Growth (YOY) -3.10%
Quarterly Earnings Growth (YOY) 11.50%
Total Debt/Equity (MRQ) 23.01%
Current Ratio (MRQ) 1.46
Operating Cash Flow (TTM) 9.08 B
Levered Free Cash Flow (TTM) -4.94 B
Return on Assets (TTM) 4.28%
Return on Equity (TTM) 7.30%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Mixed Bullish
Drug Manufacturers - General (Global) Mixed Bullish
Stock Sanofi Bullish Bullish

AIStockmoo Score

0.1
Analyst Consensus 1.5
Insider Activity NA
Price Volatility -3.0
Technical Moving Averages 2.5
Technical Oscillators -0.5
Average 0.13

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
SNY 149 B 6.88% 25.00 1.48
AZN 230 B 2.26% 30.43 6.19
AMGN 166 B 2.95% 41.04 27.94
GILD 127 B 3.03% 268.87 7.22
GRFS 6 B - 26.84 0.710
BIIB 21 B - 12.64 1.20

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Core
% Held by Institutions 10.59%

Ownership

Name Date Shares Held
Mondrian Investment Partners Ltd 31 Dec 2024 3,453,122
52 Weeks Range
45.22 (-23%) — 59.72 (0%)
Median 65.00 (9.71%)
Total 1 Hold
Firm Date Target Price Call Price @ Call
Goldman Sachs 21 Mar 2025 65.00 (9.70%) Hold 56.90

No data within this time range.

Date Type Details
08 Apr 2025 Announcement Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
08 Apr 2025 Announcement Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
03 Apr 2025 Announcement Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
03 Apr 2025 Announcement Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
03 Apr 2025 Announcement Sanofi: Information concerning the total number of voting rights and shares - February 2025
28 Mar 2025 Announcement Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
28 Mar 2025 Announcement Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
28 Mar 2025 Announcement Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
28 Mar 2025 Announcement Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
26 Mar 2025 Announcement Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
26 Mar 2025 Announcement Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
25 Mar 2025 Announcement Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
25 Mar 2025 Announcement Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
24 Mar 2025 Announcement Press Release: Availability of the Q1 2025 Aide mémoire
24 Mar 2025 Announcement Press Release: Availability of the Q1 2025 Aide mémoire
20 Mar 2025 Announcement Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
20 Mar 2025 Announcement Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
14 Mar 2025 Announcement Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
08 Mar 2025 Announcement Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
08 Mar 2025 Announcement Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
05 Mar 2025 Announcement Press release: Sanofi successfully prices EUR 1.5 billion of bond issue
05 Mar 2025 Announcement Press release: Sanofi successfully prices EUR 1.5 billion of bond issue
25 Feb 2025 Announcement Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
25 Feb 2025 Announcement Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
22 Feb 2025 Announcement Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
22 Feb 2025 Announcement Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
22 Feb 2025 Announcement Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
19 Feb 2025 Announcement Press Release: Sanofi and CD&R sign Opella share purchase agreement
19 Feb 2025 Announcement Press Release: Sanofi and CD&R sign Opella share purchase agreement
18 Feb 2025 Announcement Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
18 Feb 2025 Announcement Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
13 Feb 2025 Announcement Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
13 Feb 2025 Announcement Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
13 Feb 2025 Announcement Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
13 Feb 2025 Announcement Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
07 Feb 2025 Announcement Press Release: Execution of a share buyback agreement for up to €2 billion
07 Feb 2025 Announcement Press Release: Execution of a share buyback agreement for up to €2 billion
07 Feb 2025 Announcement Press Release: Execution of a share buyback agreement for up to €2 billion
03 Feb 2025 Announcement Press Release: Sanofi announces buy back of shares from L’Oréal
03 Feb 2025 Announcement Press Release: Sanofi announces buy back of shares from L’Oréal
31 Jan 2025 Announcement Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
31 Jan 2025 Announcement Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
30 Jan 2025 Announcement Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
30 Jan 2025 Announcement Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
29 Jan 2025 Announcement Sanofi: Information concerning the total number of voting rights and shares - December 2024
22 Jan 2025 Announcement Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
22 Jan 2025 Announcement Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
21 Jan 2025 Announcement Press Release: Opella reaches study milestone for Cialis
21 Jan 2025 Announcement Press Release: Opella reaches study milestone for Cialis
15 Jan 2025 Announcement Sanofi: Information concerning the total number of voting rights and shares – November 2024
13 Jan 2025 Announcement Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
13 Jan 2025 Announcement Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
13 Jan 2025 CNBC Moderna stock plunges nearly 17% after company lowers 2025 sales forecast by $1 billion
Show more
TTM Dividend Yield 6.88%
5Y Average Dividend Yield 4.78%
Payout Ratio 85.70%
Ex Date Announcement Date Payment Date Details
09 May 2024 26 Mar 2024 06 Jun 2024 2.037356 Cash
09 May 2024 26 Mar 2024 06 Jun 2024 2.0369079 Cash
30 May 2023 - 23 Jun 2023 1.9000852 Cash
26 May 2022 - 27 Jun 2022 0.2971788 Cash
04 May 2022 20 Apr 2022 31 May 2022 1.7967514 Cash
03 May 2021 23 Mar 2021 26 May 2021 1.906064 Cash
30 Apr 2020 05 Mar 2020 26 May 2020 1.6993994 Cash
07 May 2019 - 31 May 2019 1.722322 Cash
09 May 2018 07 Feb 2018 04 Jun 2018 1.860874 Cash
11 May 2017 16 Feb 2017 07 Jun 2017 1.577088 Cash
05 May 2016 19 Feb 2016 01 Jun 2016 1.630252 Cash
06 May 2015 25 Feb 2015 02 Jun 2015 1.618087 Cash
17 May 2010 12 Feb 2010 14 Jun 2010 1.62732 Cash
04 Jun 2007 05 Mar 2007 03 Jul 2007 1.14537 Cash
02 Jun 2006 06 Mar 2006 03 Jul 2006 0.912 Cash
02 Jun 2005 01 Mar 2005 01 Jul 2005 0.7993 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2024 4.07 2 8.45
2023 1.90 1 3.82
2022 2.09 2 4.32
2021 1.91 1 3.81
2020 1.70 1 3.50
2019 1.72 1 3.43
2018 1.86 1 4.29
2017 1.58 1 3.67
2016 1.63 1 4.03
2015 1.62 1 3.79
2010 1.63 1 5.05
2007 1.15 1 2.52
2006 0.912 1 1.98
2005 0.799 1 1.82
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria